Equities

Creative Medical Technology Holdings Inc

CELZ:NAQ

Creative Medical Technology Holdings Inc

Actions
FinancialsInvestment Banking and Brokerage Services
  • Price (USD)4.45
  • Today's Change0.110 / 2.53%
  • Shares traded2.14k
  • 1 Year change-32.58%
  • Beta4.9074
Data delayed at least 15 minutes, as of May 17 2024 20:41 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.

  • Revenue in USD (TTM)9.00k
  • Net income in USD-5.28m
  • Incorporated1998
  • Employees4.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sonnet Biotherapeutics Holdings Inc92.74k-8.43m5.73m12.00--1.88--61.75-5.28-5.280.03150.98130.0097--0.22487,728.33-87.68---194.11-------9,086.22-----138.210.00---57.76--36.64------
Hoth Therapeutics Inc0.00-7.70m5.77m2.00--0.6634-----2.02-2.020.001.780.00----0.00-70.17-157.07-77.15-177.32-----------50.670.00------31.01------
HST Global Inc0.00-146.22k5.77m1.00---------0.0279-0.02790.00-0.11280.00-------17,002.33-5,836.01---------------26.54---------0.7858------
NanoString Technologies Inc162.47m-166.43m5.77m703.00------0.0355-3.53-3.533.44-1.050.49362.074.30231,113.80-50.56-30.01-62.82-34.6635.7257.14-102.44-80.872.02-70.171.29---12.282.06-38.43--40.03--
Burzynski Research Institute Inc0.00-1.19m5.78m2.00---------0.009-0.0090.00-0.00030.00-------84,895.00-10,098.54------------------------6.18------
Titan Pharmaceuticals Inc185.00k-5.57m5.80m4.00--0.7461--31.33-7.40-7.400.2468.500.0305--4.5146,250.00-91.72-96.80-138.02-156.65-----3,010.27-406.265.55--0.07---66.97-51.1645.43---65.61--
Synaptogenix Inc0.00-12.23m5.86m5.00--0.2338-----37.38-37.380.0021.080.00----0.00-13.75-40.33-15.54-43.36------------0.00-------142.17---3.21--
Healthy Extracts Inc2.49m-2.47m5.93m----6.19--2.38-0.8588-0.85880.86110.32310.9180.492136.50---91.32-53.78-174.02-146.6565.9045.68-99.48-87.530.1636-9.720.5245--10.41105.93-151.54------
Palisade Bio Inc0.00-13.49m5.96m9.00--0.5381-----24.67-24.670.0011.820.00----0.00-96.63-132.36-111.78-165.45-------27,892.32---874.310.00-----0.781413.74--18.53--
Glucose Health Inc1.11m-456.46k5.97m2.00--6.30--5.37-0.033-0.0330.08030.0561-----------86.94---153.9547.1940.68-31.99-56.93313.11--0.00--98.3924.9416.87------
Creative Medical Technology Holdings Inc9.00k-5.28m6.04m4.00--0.6532--670.78-3.74-3.740.00646.810.00070.4291--2,250.00-42.47-110.00-43.88--60.0065.82-58,624.33-7,961.1423.53--0.00---89.84-40.8647.88------
Shineco Inc4.50m-13.99m6.16m87.00--0.0158--1.37-3.93-4.630.443160.930.05580.39320.984451,761.38-18.99-12.77-34.44-16.8411.9425.88-340.48-102.060.4903-9.040.3792-----58.35-33.86------
Soligenix Inc839.36k-6.14m6.20m13.00--1.62--7.39-0.9164-0.91640.10850.2430.0697--5.8664,566.15-51.01-75.40-872.23-154.3211.5922.83-731.60-620.02---1,677.110.5639---11.54-30.6755.50------
Cannabis Bioscience Internatnl Hlgs Inc56.94m6.94m6.23m389.000.00110.00010.67520.10940.53280.53284.294.920.591762.811.45146,384.307.83--11.73--31.96--13.24--0.685650.750.0631--12.79--177.84------
Cell MedX Corp70.00-96.91k6.24m0.00------89,170.91-0.0029-0.00290.00-0.00240.0015-------202.28-792.55-----685.71---138,442.90-3,681.84---3.17-----54.53--29.01------
Data as of May 17 2024. Currency figures normalised to Creative Medical Technology Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

6.62%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 202417.63k1.30%
Aaron Wealth Advisors LLCas of 31 Mar 202416.40k1.21%
Two Sigma Investments LPas of 31 Mar 202414.90k1.10%
HRT Financial LLCas of 31 Mar 202413.19k0.97%
Two Sigma Advisers LPas of 31 Mar 202411.74k0.87%
OMERS Administration Corp.as of 31 Mar 202411.00k0.81%
UBS Securities LLCas of 31 Mar 20243.06k0.23%
Tower Research Capital LLCas of 31 Mar 20241.68k0.12%
Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 31 Mar 2024108.000.01%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 202420.000.00%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.